Glaxosmithkline Share Price | |
---|---|
Price | 1,772.50 |
Bid | 1,772.00 |
Ask | 1,772.50 |
Change | -11.00 (-0.62%) |
Volume | 5,493,815 |
Open | 1,773.50 |
High | 1,779.00 |
Low | 1,764.50 |
Prev. Close | 1,783.50 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 4.08b |
Market Capitalisation | £72.28b |
Market Size | 1,500 |
52 Week High | 1,820.00 |
52 Week High Date | 15-May-2024 |
52 Week Low | 1,302.60 |
52 Week Low Date | 11-Jul-2023 |
# Trades | 5,940 |
---|---|
Vol. Sold | 1,295,740 |
Sold Value | £22.96m |
Vol. Bought | 1,396,027 |
Bought Value | £24.74m |
PE Ratio | 14.57648 |
Earnings | 121.60 |
Dividend | 55.50 |
Yield | 3.131% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
17-May-24 | 15:52:12 | 1,772.50 | 9 | Buy* | 1,772.00 | 1,772.50 | 159.53 | A Automatic Execution |
17-May-24 | 15:51:56 | 1,772.50 | 562 | Sell* | 1,772.50 | 1,773.00 | 9,961 | A Automatic Execution |
17-May-24 | 15:51:56 | 1,772.50 | 327 | Sell* | 1,772.50 | 1,773.00 | 5,796 | A Automatic Execution |
17-May-24 | 15:51:56 | 1,772.50 | 104 | Sell* | 1,772.50 | 1,773.00 | 1,843 | A Automatic Execution |
17-May-24 | 15:51:56 | 1,772.50 | 655 | Sell* | 1,772.50 | 1,773.00 | 11.61k | A Automatic Execution |
17-May-24 | 15:51:56 | 1,772.50 | 696 | Sell* | 1,772.50 | 1,773.00 | 12.34k | A Automatic Execution |
17-May-24 | 15:51:53 | 1,772.704 | 1,102 | Sell* | 1,772.50 | 1,773.00 | 19.54k | O Ordinary |
17-May-24 | 15:51:34 | 1,772.50 | 100 | Buy* | 1,772.00 | 1,772.50 | 1,773 | A Automatic Execution |
17-May-24 | 15:51:34 | 1,772.50 | 130 | Buy* | 1,772.00 | 1,772.50 | 2,304 | A Automatic Execution |
17-May-24 | 15:51:16 | 1,772.409 | 28 | Buy* | 1,772.00 | 1,772.50 | 496.27 | O Ordinary |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
14-May-24 | 10-May-24 | Transfer From | Julie Brown held the position of Chief Finance Officer at the time of this trade.Julie Brown | 0.00 | 7 | 41,995 | |
14-May-24 | 10-May-24 | Buy | Julie Brown held the position of Chief Finance Officer at the time of this trade.Julie Brown | 1,794.34 | GBX | 7 | 41,995 |
14-May-24 | 10-May-24 | Transfer From | Emma Walmsley held the position of CEO at the time of this trade.Emma Walmsley | 0.00 | 7 | 2,190,863 | |
14-May-24 | 10-May-24 | Buy | Emma Walmsley held the position of CEO at the time of this trade.Emma Walmsley | 1,794.34 | GBX | 7 | 2,190,863 |
19-Apr-24 | 16-Apr-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 39.79 | USD | 2,906,213 | 3,370,704 |
At GSK, we unite science, technology and talent to get ahead of disease together